Farallon Capital Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Farallon Capital Management’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-223,149	Closed	-$1.29M	–	261
2022 Q3	$1.29M	Sell	223,149 -186,568	-46%	-$1.32M	0.01%	212
2022 Q2	$2.27M	Sell	409,717 -114,262	-22%	-$944K	0.01%	207
2022 Q1	$6.04M	Hold	523,979	–	–	0.03%	176
2021 Q4	$6.64M	Buy	+523,979	New	+$7.91M	0.03%	169

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Farallon Capital Management's THRX Position: Q4 2022 in Review

Farallon Capital Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2022, closing a stake of 223,149 shares — an estimated $1.29M sold.

Farallon Capital Management first reported a position in THRX in Q4 2021 and held it in 4 quarters. The position peaked at $6.64M in Q4 2021. 47 funds tracked by Wall St. Rank hold THRX as of Q4 2022.

Farallon Capital Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Farallon Capital Management sold 223,149 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1.29M.
Farallon Capital Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Farallon Capital Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $6.64M in Q4 2021.
47 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.